Late last month, Reckitt Benckiser created a stir by unexpectedly announcing that its Suboxone tablet for treating opioid dependence will be withdrawn from the US market sometime over the next six months.

FORBES: Reckitt's Suboxone Strategy Is Really About Patients Or Profits?

It also confirms an earlier, smaller study, published as a letter in the New England Journal of Medicine last July, which tracked 2, 566 patients with opioid dependence before and after the introduction of the new OxyContin.

FORBES: Is The Era Of OxyContin Abuse Over?